BioSpace News Archive

Vitalant—the nation’s largest nonprofit, independent blood collector—serving patients in 40 states, has declared a critical shortage of blood as supplies have been significantly impacted by the coronavirus pandemic.

Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma

Executives from Alnylam and Pfizer to discuss how innovative oncology and specialty medicines are transforming commercial models and helping improve patients’ lives

Patent allowance follows compelling Phase II data showing Namodenoson resolved all cases of NASH after 12 weeks of treatment, and it reduced hepatic fibrosis and steatosis in NAFLD and NASH patients

Focus on non-small cell lung cancer with a mutation that leads to MET exon 14 skipping, and tumors with amplifications and MET fusions, including glioblastoma multiforme

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s favipiravir as a preventative measure against COVID-19 outbreaks.

End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis Suppurativa Initial promising results reported in Pyoderma Gangraenosum Part 1 of adaptive randomized trial in severe COVID-19 pneumonia fully enrolled Signed clinical collaboration agreement in oncology Cash, cash equivalents and financial assets of approximately €108.0 million as of March 31, 2020 JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage

Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF) (“Auxly” or the “Company”) has issued an additional $2 million worth of unsecured convertible debentures (collectively, the “Second Tranche”) under its $25 million unsecured convertible debenture standby facility with an institutional investor (the “Investor”) as previously announced on April 28, 2020 (the “Original Offering”).

Transparency Market Research has published a new report titled, “Gene Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global gene therapy market was valued at US$ 17.0 Mn in 2017 and is projected to expand at a CAGR of 40.0% from 2018 to 2026.

Transparency Market Research has published a new report titled, “Gynecology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.